00:59 , Aug 4, 2018 |  BioCentury  |  Finance

Hong Kong’s first wave

Having broken the seal on the new biotech chapter of Hong Kong Exchange and Clearing Ltd., the performance of Ascletis Pharma Inc. and the next few companies to go out could determine what happens to...
19:22 , Oct 20, 2017 |  BC Week In Review  |  Clinical News

AOBiome reports Phase IIb data of ammonia-oxidizing bacteria candidate for acne

AOBiome LLC (Cambridge, Mass.) said topical B244 met the primary endpoint of a greater proportion of patients who achieved a ≥2-point reduction in Investigator’s Global Assessment (IGA) score of acne severity from baseline to week...
15:44 , Oct 6, 2017 |  BC Week In Review  |  Clinical News

AOBiome begins Phase Ib/IIa of B244 for allergic rhinitis

AOBiome LLC (Cambridge, Mass.) began a Phase Ib/IIa trial of B244 to treat seasonal allergic rhinitis. The double-blind, vehicle-controlled trial will enroll up to 24 healthy volunteers and up to 42 patients with a history...
19:53 , Jan 13, 2017 |  BC Week In Review  |  Company News

iCarbonX Digital Life Alliance news

iCarbonX said seven companies joined its Digital Life Alliance, through which it aims to combine genetic, biologic and patient-generated data with sequencing and artificial intelligence technology to "instantly detect meaningful signals about health, disease and...
23:52 , Jan 6, 2017 |  BC Extra  |  Company News

iCarbonX names Digital Health Alliance members

iCarbonX Inc. (Shenzhen, China) said seven companies joined its Digital Life Alliance, through which it aims to combine genetic, biologic and patient-generated data with sequencing and artificial intelligence technology to "instantly detect meaningful signals about...
22:20 , Dec 21, 2016 |  BC Week In Review  |  Clinical News

B244: Ph II started

AOBiome began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate twice-daily B244 topical spray comprising 8×10 9 colony forming units (CFUs)/mL for 28 days in 116 patients. AOBiome LLC , Cambridge, Mass.  Product: B244...
07:00 , Sep 26, 2016 |  BC Week In Review  |  Clinical News

B244: Phase IIb started

AOBiome began a double-blind, placebo-controlled, U.S. Phase IIb trial to evaluate 4x10 9 colony forming units (CFUs)/mL B244 topical spray administered to the face twice daily for 12 weeks in about 372 adult patients. The...
07:00 , May 9, 2016 |  BioCentury  |  Product Development

Community organizers

With new papers published by the day and a flurry of big-dollar deals and financings, it's hard to separate the signal from the noise in the microbiome space. The space has become so hot that...